Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 4/20 | 0.51 |
| ▸ | EGFR | P00533 | 4/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.48 |
| ▸ | KDR | P35968 | 14/20 | 0.48 |
| ▸ | CSF1R | P07333 | 1/20 | 0.46 |
| ▸ | KIT | P10721 | 1/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
| ▸ | FLT1 | P17948 | 1/20 | 0.46 |
| ▸ | FLT4 | P35916 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12303650 | 1.00 | RET (0.51) | RETEGFRERBB2KDRCSF1R | |
| SCHEMBL2450900 | 1.00 | RET (0.51) | RETEGFRERBB2KDRCSF1R | |
| SCHEMBL2453192 | 0.89 | RET (0.52) | RETEGFRERBB2KDRCSF1R | |
| SCHEMBL2453193 | 0.89 | RET (0.52) | RETEGFRERBB2KDRCSF1R | |
| SCHEMBL12303598 | 0.89 | RET (0.52) | RETEGFRERBB2KDRCSF1R | |
| SCHEMBL2450555 | 0.83 | EGFR (0.39) | RETEGFRERBB2KDRCSF1R | |
| SCHEMBL12303593 | 0.82 | RET (0.57) | RETEGFRERBB2KDRCSF1R | |
| SCHEMBL2455955 | 0.82 | RET (0.57) | RETEGFRERBB2KDRCSF1R | |
| SCHEMBL2455951 | 0.82 | RET (0.57) | RETEGFRERBB2KDRCSF1R | |
| SCHEMBL2453292 | 0.81 | EGFR (0.54) | RETEGFRERBB2KDRCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8013153-B2 | Substituted pyrimidine kinase inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2011-09-06 | — | — | US | claimed |
| US-20070254896-A1 | SUBSTITUTED PYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-11-01 | — | — | US | claimed |
| WO-2007109783-A2 | SUBSTITUTED PYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-09-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254896-A1 | SUBSTITUTED PYRIMIDINE KINASE INHIBITORS | DTYMK, TK1, DCK | RET 577/4885EGFR 1449/4885ERBB2 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.